Real-World Experiences With Aflibercept 8mg


Experts share their real-world experience with aflibercept 8 mg, comparing it to its predecessor, aflibercept 2 mg.


Experts discuss their experiences with aflibercept 8 mg in the real world. Diana Do, MD mentions that, as an early adopter, she has started using aflibercept 8 mg in both treatment-naive and treatment-experienced patients. She notes a spectrum of responses, with some patients showing significant improvements in vision and reductions in retinal thickness, while others, particularly those with challenging, previously treated eyes, may still need closer follow-up. Kenny Fan, MD, MBA agrees with her, and emphasizes how aflibercept 8 milligrams will be used in a larger patient population with larger lesions, prior experience with other medications, and various comorbidities. He mentions that most of his patients on aflibercept 8 mg are in the Medicare population with neovascular age-related macular edema (nAMD), and he has been generally pleased with the results. However, he acknowledges the need for more data collection in the real-world setting, especially concerning the label extension after the initial three-month injections.

This summary was AI-generated and edited for clarity.

Related Videos
Sean Adrean, MD: Impact of Baseline VA on Aflibercept 8 mg Outcomes in DME | Image Credit: Linkedin
Mark Barakat, MD: Stable IOP Outcomes After Aflibercept 8 mg in DME | Image Credit: Retina Macula Institute of Arizona
Roger Goldberg, MD: Impact of Dual Inhibition on Hard Exudates in DME | Image Credit: Bay Area Retina Associates
Deepayan Kar, PhD, MS: A Virtual Reality Approach to Contrast Sensitivity in AMD | Image Credit: LinkedIn
Dolly Chang, MD, PhD | Image Credit: LinkedIn
Daniel Su, MD: | Image Credit: Retina Vitreous-Associates Medical Group
Daniela Ferrara, MD, PhD: Machine Learning Predicts Functional Outcomes in DME | Image Credit: Ophthalmology Innovation Summit
Ashkan Abbey, MD: 3-Year Efficacy of Pegcetacoplan for Geographic Atrophy | Image Credit: Texas Retina AssociatesImage Credit:
© 2024 MJH Life Sciences

All rights reserved.